Hepatobiliary Cancer Coverage from Every Angle

James J. Harding, MD, on New Data on Neratinib for HER2-Positive Biliary Tract Cancer

Posted: Thursday, October 6, 2022

James J. Harding, MD, of Memorial Sloan Kettering Cancer Center, discusses findings from the SUMMIT trial of neratinib for patients with HER2-positive biliary tract cancer, its modest activity, and other agents being considered for investigational regimens that might improve responses.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.